|
1
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
2
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vanhoefer U, Rougier P, Wilke H, et al:
Final results of a randomized phase III trial of sequential
high-dose methotrexate, fluorouracil, and doxorubicin versus
etoposide, leucovorin, and fluorouracil versus infusional
fluorouracil and cisplatin in advanced gastric cancer: A trial of
the European Organization for Research and Treatment of Cancer
Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol.
18:2648–2657. 2000.
|
|
4
|
Lavin PT, Bruckner HW and Plaxe SC:
Studies in prognostic factors relating to chemotherapy for advanced
gastric cancer. Cancer. 50:2016–2023. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilson D, Hiller L and Geh JI: Review of
second-line chemotherapy for advanced gastric adenocarcinoma. Clin
Oncol (R Coll Radiol). 17:81–90. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boku N, Yamamoto S, Fukuda H, et al:
Fluorouracil versus combination of irinotecan plus cisplatin versus
S-1 in metastatic gastric cancer: a randomised phase 3 study.
Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee J, Lim T, Uhm JE, et al: Prognostic
model to predict survival following first-line chemotherapy in
patients with metastatic gastric adenocarcinoma. Ann Oncol.
18:886–891. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chau I, Norman AR, Cunningham D, Waters
JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in
locally advanced and metastatic esophago-gastric cancer-pooled
analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol. 22:2395–2403. 2004.
View Article : Google Scholar
|
|
9
|
Cunningham D, Hole D, Taggart DJ, Soukop
M, Carter DC and McArdle CS: Evaluation of the prognostic factors
in gastric cancer: the effect of chemotherapy on survival. Br J
Surg. 74:715–720. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu CH, Yeh KH, Chen LT, et al: Weekly
24-hour infusion of high-dose 5-fluorouracil and leucovorin in the
treatment of advanced gastric cancers. An effective and low-toxic
regimen for patients with poor general condition. Oncology.
54:275–280. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim do H, Park SH, Park KW, et al:
Retrospective analyses of cisplatin-based doublet combination
chemotherapy in patients with advanced gastric cancer. BMC Cancer.
10:5832010.PubMed/NCBI
|
|
12
|
Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH,
Roh JK and Chung HC: A phase II study of S-1 monotherapy
administered for 2 weeks of a 3-week cycle in advanced gastric
cancer patients with poor performance status. Br J Cancer.
97:4584–4563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hosokawa A, Sugiyama T, Ohtsu A, et al:
Long-term outcomes of patients with metastatic gastric cancer after
initial S-1 monotherapy. J Gastroenterol. 42:533–538. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
15
|
Egawa T, Kubota T, Nagashima A, et al:
Usefulness of weekly administration of paclitaxel for advanced or
recurrent gastric cancer. Gan To Kagaku Ryoho. 31:877–881. 2004.(In
Japanese).
|
|
16
|
Futatsuki K, Wakui A, Nakao I, et al: Late
phase II study of irinotecan hydrochloride (CPT-11) in advanced
gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To
Kagaku Ryoho. 21:1033–1038. 1994.(In Japanese).
|
|
17
|
Kang JH, Lee SI, Lim DH, et al: Salvage
chemotherapy for pretreated gastric cancer: a randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bang YJ: Capecitabine in gastric cancer.
Expert Rev Anticancer Ther. 11:1791–1806. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hwang JE, Kim HN, Kim DE, et al:
Prognostic significance of a systemic inflammatory response in
patients receiving first-line palliative chemotherapy for recurred
or metastatic gastric cancer. BMC Cancer. 11:4892011. View Article : Google Scholar
|
|
20
|
Maehara Y, Sugimachi K, Ogawa M, Kakegawa
T, Shimazu H and Tomita M: Influence of preoperative performance
status on survival time of patients with advanced gastric cancer
following noncurative resection. Anticancer Res. 13:201–203.
1993.PubMed/NCBI
|
|
21
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koizumi W, Akiya T, Sato A, et al: Phase
II study of S-1 as first-line treatment for elderly patients over
75 years of age with advanced gastric cancer: the Tokyo Cooperative
Oncology Group study. Cancer Chemother Pharmacol. 65:1093–1099.
2010.PubMed/NCBI
|
|
23
|
Tsushima T, Hironaka S, Boku N, et al:
Safety and efficacy of S-1 monotherapy in elderly patients with
advanced gastric cancer. Gastric Cancer. 13:245–250. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pasini F, Fraccon AP and DE Manzoni G: The
role of chemo-therapy in metastatic gastric cancer. Anticancer Res.
31:3543–3554. 2011.
|
|
25
|
Ando T, Hosokawa A, Kajiura S, et al:
Efficacy of weekly paclitaxel in patients with advanced gastric
cancer: refractory to docetaxel-based chemotherapy. Gastric Cancer.
Jan 18–2012.(Epub ahead of print).
|
